JAK Inhibitors in Atopic Dermatitis

EP: 1.Heterogenous Presentation of Atopic Dermatitis

EP: 2.Burden of Atopic Dermatitis and its Impact on Patient’s Quality of Life

EP: 3.Patient’s Goals and Atopic Dermatitis Treatment Selection

EP: 4.Talking to Patients about Atopic Dermatitis Treatment Response

EP: 5.Use of PRO in Atopic Dermatitis Clinical Practice

EP: 6.Incorporating Patient Preferences in the Treatment of Atopic Dermatitis

EP: 7.Changing Standard of Care in Atopic Dermatitis

EP: 8.Unmet Needs and Gaps in AD

EP: 9.Looking Beyond Type 2 Inflammation in Atopic Dermatitis

Now Viewing

EP: 10.JAK Inhibitors in Atopic Dermatitis

EP: 11.Safety Profile of JAK Inhibitors and their Use in Atopic Dermatitis

EP: 12.Monitoring Schedule for JAK Inhibitors in Atopic Dermatitis

EP: 13.Data from LEVEL UP Trial with Upadacitnib in Atopic Dermatitis

EP: 14.Long-term Safety of JAK Inhibitors in Atopic Dermatitis

EP: 15.Use of JAK Inhibitors and Systemic Treatments for Atopic Dermatitis

EP: 16.Treatment of Bio-Naïve Patients or Those Progressing on Topical or Biologic Atopic Dermatitis Therapy

EP: 17.Emerging Treatments for Atopic Dermatitis

Video content above is prompted by the following:

• A number of JAK inhibitors, both oral (abrocitinib, upadacitnib) and topical (ruxolitinib cream), are FDA approved for atopic dermatitis.
  • How have JAK inhibitors evolved over the years?
  • How have differences between JAK inhibitors led to differences in their safety and efficacy profiles?